微信直播

Prof. Mien-Chie Hung: 免疫治疗前景广阔

Published at: 2015年第1卷第S1期

吴晓珺
关键词:

编者按:第十二届上海国际乳腺癌论坛于10月20日至21日在上海举行,此次会议由中国抗癌协会乳腺癌专业委员会、复旦大学附属肿瘤医院、上海市抗癌协会等多家单位联合主办,是乳腺癌治疗及研究的盛会。众多国内外乳腺癌领域的专家,如吴炅教授,邵志敏教授,Prof. Michael Gnant, Prof. Fiona MacNeil, Prof. Ian Ogilvie Ellis等悉数到场。Prof. Mien-Chie Hung也远道而来,并在会议上进行“以标记物介导的PARP抑制剂与免疫调控疗法的联合治疗”的精彩演讲。Prof. Mien-Chie Hung拥有丰富的乳腺癌免疫治疗经验,我们有幸邀请他对乳腺癌免疫治疗方法的优缺点,涉及乳腺癌治疗及药物研究的重要细胞信号分子和癌症基因的研究,乳腺癌治疗的未来展望等进行分享。

人物聚焦:Prof. Mien-Chie Hung

Prof. Mien-Chie Hung(洪明奇教授), a Taiwanese-born American molecular biologist and cancer researcher. He is the Professor and Chair, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center in Houston, Texas.

Prof. Hung received his bachelor's and master's degrees in Chemistry and biochemistry from National Taiwan University in Taipei, Taiwan. In 1983, he earned his Ph.D degree in biochemistry from Brandeis University, in the United States. In 1984, he worked at Massachusetts Institute of Technology, under the supervision of world-renowned molecular biologist, Dr. Robert A. Weinberg.

图1. Prof. Mien-Chie Hung演讲” 以标记物介导的PARP抑制剂与免疫调控疗法的联合治疗”

Prof. Mien-Chie Hung的研究集中于癌症细胞信号通路,原癌基因与抑癌基因,以及癌症免疫治疗领域,他曾参与发现了Her2/neu,并致力研究癌症相关分子机制,为免疫治疗及靶向药物的研发做出了长足的贡献。他在采访中非常乐观地表达了他对免疫治疗,尤其是癌症免疫检查点疗法(immune checkpoint therapy)前景的看好。但他也指出,免疫检查点疗法药物并不是仙丹, PD-1是一种免疫检查点分子,免疫检查点疗法药物多通过阻隔PD-1和PD-L1的信号传导起到治疗作用,但对PD-1阴性的癌症无法起到很好的效果。现在研究人员正在开发通过旁侧效应(bystander effect)将免疫检查点疗法运用到PD-1阴性的癌症治疗中。

Prof. Hung十分认同分子机制研究在癌症治疗中的重要性。除了细胞信号分子,调控及表达癌症相关分子的原癌基因和抑癌基因也非常重要。他用p53作为例子,p53是一个人体抑癌基因,在癌症中通常发生突变而沉默,进而使癌症不受其控制而发生。虽然已被发现了约30年,但目前仍没有针对它的药物问世。但Prof. Hung坚定地相信,虽然技术上比较困难,且需要花更久的时间,但针对p53乃至其他抑癌基因的药物最终一定能够出现。说到“万物之源”——基因,就不得不提基因治疗。Prof. Hung表达了对基因技术的观点,他指出由于技术壁垒,基因治疗虽然有前景,但在未来的几十年中还不会成为癌症治疗的主要手段。然而基因治疗的一些技术可以与靶向治疗等目前主要的治疗方式结合,CAR-T细胞免疫疗法中就应用了基因治疗技术。基因治疗不一定会成为主流治疗方式,但仍能在乳腺癌治疗方面发挥至关重要的作用。

更多精彩内容分享,欢迎观看视频:

采访问答

1. Would you kindly share some immunotherapy methods on breast cancer and their pros and cons with us?

2. What do you think about the immunotherapy on breast cancer in the near future?

3. Many anti-cancer drugs effect the cell signal transduction, could you introduce breast-cancer-related signal transduction and its applications or potentials to become a therapy or drug for us?

4. We know that you study oncogenes and anti-oncogenes, their roles in the carcinogenesis and the growth factor receptors and transcript factors they code. Would you share some oncogene/ anti-oncogene research on breast cancer and breast cancer drug/ therapy development?

5. Since there are so many oncogenes and anti-oncogenes that can regulate carcinogenesis, what do you think about gene therapy on breast cancer? Will gene therapy become a leading way to treat breast cancer?

采写编辑:吴晓珺,AME Publishing Company

视频剪辑:麦雪芳,AME Publishing Company

comments powered by Disqus

附件